Is Electronic-IFU an Option?

by | Feb 26, 2021 | Documents, IFU, Medical Devices, Quality, Quality Systems, Software, Validation, Virtual

Changes in technology call for changes in the ways we use that technology. This means that the instructions for use which are used as a tool to help users operate a medical device must also change and adapt.

While using paper-based instructions for use (IFU) has been a standard practice, there are several risks associated with it that come to light when the instructions need to be updated due to post-market feedback or continuous improvement activities.

With the rise in a digital media interaction, the idea of electronic-Instructions for use is becoming more popular. This allows the manufacturer to update the instructions for use whenever there is a design change or a recommended change in the operation due to a risk identified post-market.

The question then arises- what are the requirements around it? e-IFUs may be provided for any device type however, a safe practice would be to also provide paper IFUs. If you plan on providing only e-IFUs, then the users must be made aware of such arrangements. Additionally, e-IFUs available on the company’s website/app must be kept up to date for each version/model of the device still in the field.

Since IFUs are considered part of the product’s label, e-IFUs must also comply with the labeling requirements applicable to the product. As all product labels (including paper IFUs) undergo quality control, e-IFUs must also be subjected to the same level of quality control.1

In the case where an IFU is provided electronically only, the risk associated with providing an electronic IFU must be considered in the product’s risk assessment file and appropriate human factors analysis must be conducted.

Companies may think that e-IFU is an easy way to go and reduces the financial burden on having to print copies of paper IFU, on the contrary, I think it adds another risk level to the product such as an obsolete version being available on the website, quality control of e-IFUs, language requirements for labels and many more.

Need expert regulatory guidance on your product label? Call us today at +1 248-987—497 or email us at info@emmainternational.com


1EU Commission (March 2012) COMMISSION REGULATION (EU) No 207/2012 of 9 March 2012 on electronic instructions for use of medical devices retrieved on 02/18/2021 from https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:072:0028:0031:EN:PDF

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This